Table 1 Patient, tumor, and treatment characteristics (n = 1590)

Age (range, years)

 < 60

331 (21%)

[60–70]

814 (51%)

 > 70

445 (28%)

Median PSA (ng/mL)

6.0 [4.6, 8.0]

PSA (ng/mL)

 < 10

1353 (85%)

[10–20]

231 (14%)

 > 20

6 (1%)

Gleason Scores

6

546 (34%)

7

993 (62%)

8

45 (3%)

9

6 (1%)

NCCN Risk

Low

474 (30%)

Intermediate

1061 (67%)

High

55 (3%)

Total number cores

 < 12

56 (4%)

12

1503 (94%)

 > 12

31 (2%)

Median % core involvement

25.0 [16.7, 41.7]

Core involvement

0–25

893 (56%)

26–50

535 (33%)

51–75

124 (7%)

75–100

38 (3%)

Median Prostate CTV (cc)

77.8 [61.3, 99.1]

Prostate CTV (cc)

 < 50

149 (10%)

50–100

878 (55%)

101–150

246 (16%)

151–200

36 (2%)

 > 200

44 (3%)

Unknown

233 (15%)